ストックスクリーナーアプリを入手
25.93
3.39%
-0.925
前日終値:
$26.85
開ける：
$26.56
24時間の取引高:
96,518
Relative Volume:
0.13
時価総額：
$1.72B
収益：
$5.79M
当期純損益:
$-199.61M
株価収益率:
-8.613
EPS:
-3.01
ネットキャッシュフロー:
$-188.48M
1週間 パフォーマンス:
+1.13%
1か月 パフォーマンス:
-2.41%
6か月 パフォーマンス:
+8.67%
1年 パフォーマンス:
+6.27%
1日の値動き範囲:
$25.84
$26.74
1週間の範囲:
$25.00
$26.96
52週間の値動き範囲:
$14.40
$30.50
Celldex Therapeutics Inc Stock (CLDX) Company Profile
CLDX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
25.91 | 1.78B | 5.79M | -199.61M | -188.48M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.63 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.34 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.84 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-21 | 開始されました | Mizuho | Outperform |
| 2025-10-13 | 開始されました | Barclays | Underweight |
| 2025-04-28 | 開始されました | Canaccord Genuity | Buy |
| 2025-03-20 | 開始されました | Morgan Stanley | Overweight |
| 2025-02-13 | 開始されました | UBS | Buy |
| 2024-10-07 | 開始されました | Citigroup | Buy |
| 2024-09-30 | 開始されました | Goldman | Neutral |
| 2024-09-27 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | 開始されました | Stifel | Buy |
| 2024-06-11 | 開始されました | Wolfe Research | Outperform |
| 2023-12-20 | 開始されました | TD Cowen | Outperform |
| 2023-11-10 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | 開始されました | Wells Fargo | Underweight |
| 2021-09-17 | 開始されました | Jefferies | Buy |
| 2021-09-10 | 開始されました | SVB Leerink | Outperform |
| 2021-07-22 | 開始されました | Guggenheim | Buy |
| 2020-02-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-08-01 | 再開されました | H.C. Wainwright | Buy |
| 2016-11-07 | 開始されました | Aegis Capital | Buy |
| 2016-03-08 | ダウングレード | Jefferies | Buy → Hold |
| 2016-03-07 | ダウングレード | Guggenheim | Buy → Neutral |
| 2016-03-07 | ダウングレード | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | ダウングレード | Wedbush | Outperform → Neutral |
| 2016-03-01 | 開始されました | H.C. Wainwright | Buy |
| 2015-08-11 | 繰り返されました | Brean Capital | Buy |
| 2015-08-11 | 繰り返されました | Oppenheimer | Outperform |
| 2015-08-11 | 繰り返されました | ROTH Capital | Buy |
| 2015-06-02 | 繰り返されました | WBB Securities | Strong Buy |
| 2014-11-17 | 繰り返されました | ROTH Capital | Buy |
| 2014-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2013-07-08 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2013-03-08 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2013-02-26 | 繰り返されました | Oppenheimer | Outperform |
| 2013-01-10 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2012-10-02 | 繰り返されました | Oppenheimer | Outperform |
| 2012-09-14 | 繰り返されました | Cantor Fitzgerald | Buy |
すべてを表示
Celldex Therapeutics Inc (CLDX) 最新ニュース
Day Trade: cờ tướng họcEarnings Growth Summary & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Sees Large Growth in Short Interest - MarketBeat
Pullback Watch: Whats the fair value of Celldex Therapeutics Inc stockWeekly Trend Report & Long-Term Growth Plans - baoquankhu1.vn
Reassessing Celldex Therapeutics (CLDX) Valuation As Shares Trade At A Discount To DCF Estimates - Sahm
Value Recap: Is Celldex Therapeutics Inc stock resilient to inflationFed Meeting & Smart Allocation Stock Tips - Bộ Nội Vụ
Celldex Therapeutics, Inc. (CLDX) Stock Analysis: Unpacking a 107.86% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Celldex Therapeutics SVPs Engage In Heavy Transactions - AOL.com
Celldex Therapeutics (NASDAQ:CLDX) Trading Down 7.5%Here's Why - MarketBeat
Market Pulse: Can Celldex Therapeutics Inc disrupt its industryMarket Rally & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Can Celldex Therapeutics Inc disrupt its industry2025 Geopolitical Influence & Reliable Price Action Trade Plans - baoquankhu1.vn
How Advancing Antibody Pipeline And 2027 Cash Runway At Celldex Therapeutics (CLDX) Has Changed Its Investment Story - Sahm
Will Celldex Therapeutics Inc. stock see insider buyingPortfolio Risk Summary & Detailed Earnings Play Strategies - ulpravda.ru
Will Celldex Therapeutics Inc. stock deliver better than expected guidanceQuarterly Profit Report & Advanced Swing Trade Entry Plans - Улправда
Why Celldex Therapeutics Inc. (TCE2) stock could be top winnerJuly 2025 Chart Watch & Fast Entry High Yield Tips - Улправда
Is Celldex Therapeutics (CLDX) Pricing Reflect Its DCF Upside After Recent Share Swings - Sahm
Will Celldex Therapeutics Inc. stock attract more institutional investors2025 Market Overview & Precise Swing Trade Alerts - Улправда
Can Celldex Therapeutics Inc. stock deliver surprise earnings beatStop Loss & Daily Growth Stock Investment Tips - Улправда
How Celldex Therapeutics Inc. stock trades during market volatility2025 Analyst Calls & Fast Entry Momentum Trade Alerts - Улправда
Is Celldex Therapeutics Inc. stock a good choice for value investorsMarket Sentiment Summary & Smart Allocation Stock Reports - ulpravda.ru
Chronic Spontaneous Urticaria Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Allakos, AstraZeneca, Biosana, Celldex Therapeutics, Celltrion, Eli Lilly and Company - Barchart.com
Celldex Therapeutics Builds Momentum Around Barzolvolimab And Bispecific Antibody Programs - RTTNews
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Celldex Therapeutics (CLDX) Stock Analysis: Biotechnology Innovator with Over 100% Upside Potential - DirectorsTalk Interviews
Celldex stock rating reiterated as Overweight by Cantor Fitzgerald - Investing.com Canada
Celldex Therapeutics (NASDAQ:CLDX) Trading 4.1% HigherShould You Buy? - MarketBeat
Simplify Asset Management Inc. Invests $2.20 Million in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Short Interest in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Declines By 20.9% - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Stock Price Crosses Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Celldex Therapeutics, Inc. (CLDX) Stock Analysis: Strong Buy Ratings and Nearly 96% Upside Potential - DirectorsTalk Interviews
Barclays Lifts PT on Celldex Therapeutics (CLDX) to $24 From $21 - Insider Monkey
We're Hopeful That Celldex Therapeutics (NASDAQ:CLDX) Will Use Its Cash Wisely - Yahoo Finance
Corient Private Wealth LLC Purchases Shares of 201,717 Celldex Therapeutics, Inc. $CLDX - MarketBeat
12 Small Cap Stocks to Buy with Huge Upside Potential - Insider Monkey
Celldex Therapeutics (CLDX): Assessing Valuation After a Recent Share Price Uptick - Sahm
Income Plays: How sustainable is Celldex Therapeutics Inc. stock dividend payoutGDP Growth & AI Powered Trade Plan Recommendations - Улправда
Will Celldex Therapeutics Inc. stock outperform value stocksJuly 2025 Levels & Weekly High Potential Stock Alerts - DonanımHaber
Will Celldex Therapeutics Inc. stock outperform growth indexesJuly 2025 Spike Watch & Verified Swing Trading Watchlists - DonanımHaber
Will Celldex Therapeutics Inc. stock outperform tech sector in 2025Weekly Trade Summary & Low Volatility Stock Suggestions - Улправда
How Celldex Therapeutics Inc. stock performs after earningsInflation Watch & Stepwise Entry and Exit Trade Signals - Улправда
Aug Summary: Will Celldex Therapeutics Inc. stock see insider buying2025 Momentum Check & Real-Time Buy Signal Alerts - Улправда
Barclays Maintains Celldex Therapeutics (CLDX) Underweight Recommendation - Nasdaq
Celldex Therapeutics (NASDAQ:CLDX) Price Target Raised to $24.00 at Barclays - MarketBeat
Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
TFG Asset Management GP Ltd Has $6.43 Million Stake in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Bellevue Group AG Has $67.31 Million Stock Holdings in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Eventide Asset Management LLC Lowers Stake in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Celldex Therapeutics, Inc. $CLDX Shares Sold by Redmile Group LLC - MarketBeat
Should Celldex’s Global Phase 3 EMBARQ Trial for Barzolvolimab in Inducible Urticaria Require Action From CLDX Investors? - Sahm
HighVista Strategies LLC Purchases New Position in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Stock Price Down 4.5%Should You Sell? - MarketBeat
Celldex Therapeutics Inc (CLDX) 財務データ
収益
当期純利益
現金流量
EPS
4.38%
1.95%
大文字化:
|
ボリューム (24 時間):